财务方面，公司收益自截至2019年3月31日止年度的1.957亿港元增至截至2020年3月31日止年度的2.484亿港元。收益增加主要由于来自专科医疗服务的收益增加。其中透过专科医生提供服务产生的收益由截至2019年3月31日止年度的1.923亿港元增加4010万港元或20.9%至截至2020年3月31日止年度的2.324亿港元。The Zhitong Finance App learned that, according to the Hong Kong Stock Exchange's disclosure on December 30, Zhongzhuo Medical Holdings Co., Ltd. submitted a listing application to the main board of the Hong Kong Stock Exchange, and CICC is the sole sponsor. It is worth noting that the company submitted listing applications to the main board of the Hong Kong Stock Exchange on October 29 last year and June 15 this year. Currently, both applications have expired.
The company is a comprehensive private healthcare service provider in Hong Kong. Its specialists are renowned in their respective fields of expertise, providing specialist medical services, which are complemented by a variety of specialist medical services and medical management services. According to Frost & Sullivan, the company ranked sixth among multi-specialty medical centre operators in Hong Kong. In 2020, the market share in terms of revenue generated from the provision of specialist services (including internal medicine and surgery-related specialist services) was about 1.4%. Also, according to the same data, the company ranked fourth among all private multi-specialty medical centre operators in Hong Kong in terms of revenue generated from providing internal medicine specialist services.
As of 2021, the company operated three medical centers under the “Zhongzhuo Medical” brand, including a comprehensive flagship medical center, Zhongzhuo Medical II, and a psychiatric center; the company operated two imaging and diagnostic centers and a laboratory under the “Hong Kong Medical Diagnostic Center” subsidiary brand, all located in Central, Hong Kong. The company's clients mainly include individuals seeking medical services from the company's specialists.
On the financial side, the company's revenue increased from HK$195.7 million for the year ended March 31, 2019 to HK$248.4 million for the year ended March 31, 2020. The increase in revenue was mainly due to increased revenue from specialist medical services. Revenue generated from services provided through specialists increased by HK$40.1 million or 20.9% from HK$192.3 million for the year ended 31 March 2019 to HK$232.4 million for the year ended 31 March 2020.
Revenue increased from HK$248.4 million for the year ended 31 March 2020 to HK$251.4 million for the year ended 31 March 2021. The increase in revenue was mainly due to increased revenue from allied health services, partially offset by a decrease in revenue from specialist health services. Revenue from services provided by specialists decreased by HK$14.4 million or 6.2% from HK$232.4 million for the year ended 31 March 2020 to HK$218 million for the year ended 31 March 2021.
The company's revenue increased from HK$121.3 million for the six months ended September 30, 2020 to HK$166 million for the six months ended September 30, 2021.